Thermo Fishr Sci - TMO STOCK NEWS

Thermo Fisher Scientific (NYSE: TMO) announced its intention to redeem approximately $2.6 billion of Senior Notes on January 15, 2021. This includes €0.5 billion of 2.150% Senior Notes due 2022, $1.0 billion of 3.000% Senior Notes due 2023, and $1.0 billion of 4.150% Senior Notes due 2024. The redemption price will be based on either the principal amount or the present value of remaining scheduled payments. Funding for this redemption will come from cash on hand. Thermo Fisher continues to lead in scientific innovation with annual revenues exceeding $25 billion.

Thermo Fisher Scientific (NYSE: TMO), a leader in serving science, will have CEO Marc N. Casper present virtually at the Evercore ISI HealthCONx Conference on December 1, 2020, at 1:00 p.m. (EST). The presentation will cover the company's insights regarding the impact of the COVID-19 pandemic and outline expectations for future financial performance. Thermo Fisher, with over $25 billion in annual revenue, aims to support customers in making the world healthier, cleaner, and safer. Access the live webcast on their website.

Thermo Fisher Scientific (NYSE: TMO) has appointed R. Alexandra "Alex" Keith to its board of directors, expanding the board to 13 members. Keith, CEO of Procter & Gamble's global Beauty business, oversees a $13 billion segment with 10,000 employees. This appointment is expected to strengthen Thermo Fisher's brand with customers worldwide. Marc N. Casper, CEO of Thermo Fisher, praised her leadership and innovation. Keith has been recognized as one of the "Fortune Most Powerful Women International" from 2018 to 2020.

Thermo Fisher Scientific (NYSE:TMO) has partnered with Innoforce to establish a new pharma services facility in Hangzhou, China, aimed at integrated biologics and sterile drug development. Expected to be operational by 2022, this state-of-the-art facility will enhance Thermo Fisher's global pharma network, offering services that align with stringent regulatory guidelines. The collaboration is poised to meet rising demand for biologics in China and facilitate drug development for both regional and global clients.

Thermo Fisher Scientific has declared a quarterly cash dividend of $0.22 per share, payable on January 15, 2021. Shareholders on record as of December 15, 2020 will receive this dividend. The company also authorized a significant $2.5 billion share repurchase program, replacing the previous $1 billion authorization. This repurchase program does not have an expiration date, indicating the company's confidence in enhancing shareholder value.

Thermo Fisher Scientific (TMO) announced impressive Q3 2020 results, reporting revenue of $8.52 billion, a 36% increase from Q3 2019. GAAP diluted EPS soared 157% to $4.84, while adjusted EPS rose 91% to $5.63. COVID-19 related revenue amounted to $2.0 billion, bolstering the company's pandemic response efforts, including new testing solutions and the opening of a new facility in Singapore. The company also donated over $25 million to support HBCUs during the pandemic. Overall, TMO is positioned for strong future growth.

Thermo Fisher Scientific (NYSE:TMO) has expanded the Emergency Use Authorization (EUA) for its TaqPath COVID-19 Combo Kit to incorporate nasal swab specimens collected via Everlywell's COVID-19 Test Home Collection Kit. This partnership aims to enhance access to PCR-based testing, increasing convenience for individuals. With more than 10,000 employees participating in a pilot program for at-home testing, Thermo Fisher aims to bolster workplace safety as organizations seek to manage COVID-19 risks. Note that this home collection kit is authorized under an EUA and not FDA approved.

Thermo Fisher Scientific (NYSE: TMO) plans to establish a new sterile filling facility in Singapore with an investment of US$130 million. This facility, supported by the Singapore Economic Development Board, aims to enhance manufacturing capacity for therapies and vaccines, responding to future health crises. Once operational in 2022, it will include the region's first high-speed sterile line for live virus filling, capable of producing 30 million doses per month and employing over 300 people.

Thermo Fisher Scientific (NYSE: TMO) has launched two new SARS-CoV-2 antibody tests: the OmniPATH COVID-19 Total Antibody ELISA and EliA SARS-CoV-2-Sp1 IgG tests. The OmniPATH test has received Emergency Use Authorization (EUA) from the FDA for detecting total antibodies, while the EliA test is commercially available with its EUA currently under review. These tests enhance the company’s portfolio in response to the COVID-19 pandemic, allowing laboratories to conduct testing with greater efficiency and flexibility. Thermo Fisher's annual revenue exceeds $25 billion.